Eyes On The Prize: Two More Aflibercept Biosimilars Get EU Nods

In the wake of Biocon’s debut positive opinion for an aflibercept rival to Eylea just over a year ago, two further companies – Sandoz and Samsung Bioepis – have now secured coveted endorsements from the European Medicines Agency for their own versions of the ophthalmic biosimilar. Meanwhile, Teva has received a CHMP nod for another Imnovid generic.